Edition:
India

People: Anavex Life Sciences Corp (AVXL.OQ)

AVXL.OQ on NASDAQ Stock Exchange Capital Market

2.85USD
9:58pm IST
Change (% chg)

$-0.01 (-0.35%)
Prev Close
$2.86
Open
$2.86
Day's High
$2.91
Day's Low
$2.84
Volume
13,438
Avg. Vol
127,135
52-wk High
$4.08
52-wk Low
$1.25

Toutain, Stephan 

Mr. Stephan Toutain is Senior Vice President - Operations of the Company. Toutain brings more than 25 years of drug development, general management, operations, commercial development, market access, and sales and marketing leadership with particular expertise in neurology and orphan drug markets globally. Before joining Anavex, he held the role of CCO at Interleukin Genetics. He also worked with Alnylam Pharmaceuticals to build its early access program. Previously, he led Global Commercial Development for Sarepta Therapeutics and served as General Manager for Alexion Pharmaceuticals in Europe. Mr. Toutain has also held various U.S. commercial, marketing and product management positions with Alexion Pharmaceuticals, Celgene Corporation, and Johnson & Johnson. He received a Master of Business Administration from the University of North Carolina, and a Master of Engineering in Biotechnology from the University of Nancy II in France.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --